Innoquest Diagnostics

Name

Innoquest Diagnostics

Legal name

Innoquest Diagnostics Pte Ltd

Website

https://innoquest.com.sg

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

501–1,000 employees

Ownership category

akta.pro rank

Product category

Clinical Laboratory Services

NAICS

Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Clinical Chemistry & Immunoassay Laboratories (HLAFAMAB)

akta.pro secondary industries

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics) (HLAHAAAN), Microbiology & Infectious Disease Testing Laboratories (HLAFAMAD)

Keywords

• Clinical laboratory services
• Diagnostic testing
• Pathology services
• Preventive health screening
• Medical laboratory diagnostics

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain

Revenue model

1. Diagnostic Laboratory Testing Services: Provides comprehensive diagnostic testing services to clinicians, hospitals, and medical centers. Services include laboratory tests, on-site screening, phlebotomy services, and courier specimen collection. Revenue is generated through billable laboratory tests ordered by healthcare providers.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Innoquest Diagnostics operates a centralized clinical medical laboratory and satellite hospital laboratories that perform diagnostic testing on specimens collected from clinicians, hospitals and medical centres across Singapore. Its core offering is the execution and reporting of pathology, serology, microbiology, haematology, biochemistry, immunology, molecular and special chemistry tests, supported by mobile phlebotomy and courier services that bring specimen collection and report delivery to healthcare providers and their patients.

Product overview

Innoquest Diagnostics is a community-based medical laboratory operating seven facilities in Singapore with Roche total laboratory automation capable of processing over 10,000 patient episodes daily. The company offers a comprehensive portfolio of diagnostic services centered around its core laboratory testing services, supported by specialized product lines including HealthIQ (a chronic disease risk assessment product developed in partnership with Nightingale Health providing predictive risk scores for multiple chronic conditions), and an extensive test menu covering genetic testing (BRCA, Ambry Genetics), prenatal screening (Panorama NIPT, Harmony NIPT), cardiac biomarkers (Troponin T, Lipoprotein(a)), thyroid function tests (TRAb, TSI), infectious disease testing (QuantiFERON-TB, Urea Breath Test), and specialized diagnostics (LiverFASt, ROMATM, Preeclampsia Screening). Additional services include health screening, on-site screening, phlebotomy services, and courier services, all supported by an e-Results Portal for electronic result delivery.

Differentiator

Problem solved

Functional benefit

Brands

• HealthIQ: Innovative product line that provides comprehensive understanding of chronic disease risks. It includes risk scores for multiple chronic conditions, commonly used blood markers and unique insights to special lipids, nutrition and systemic inflammation. The technology was developed by Nightingale Health.

Products and services

• Laboratory Testing Services Comprehensive diagnostic testing services including pathology, serology, microbiology, haematology, biochemistry, immunology, molecular and special chemistry testing for clinicians, hospitals and medical centres.
• HealthIQ Chronic Disease Risk Assessment Innovative product line providing comprehensive understanding of chronic disease risks, including risk scores for multiple chronic conditions, commonly used blood markers and unique insights into special lipids, nutrition and systemic inflammation, using Nightingale Health's technology.
• HealthIQ Interpretation Service Risk interpretation service providing clinicians with detailed analysis of HealthIQ chronic disease risk scores and blood-marker insights.
• Health Screening Preventive health screening services covering childhood through old age to help prevent, diagnose and treat infections, allergies, chronic diseases, cancer and other medical conditions.
• On-Site Screening Mobile screening services deployed at medical centres and facilities throughout Singapore for convenient on-site preventive and diagnostic screening.
• Phlebotomy Services Specimen collection services including mobile phlebotomy teams deployed for patient convenience at provider sites and medical centres.
• Courier Services Specimen transportation and medical report delivery services for healthcare facilities and clinics across Singapore.
• BRCA 1 & 2 Breast Cancer Test Genetic test analysing BRCA1 and BRCA2 gene mutations to estimate risk of hereditary breast and ovarian cancer (HBOC) syndrome.
• LiverFASt Test Innovative diagnostic test determining the degree of liver damage in patients with various liver diseases.
• Ambry Genetics Testing Genetic testing services including cancer genetic risk assessment, hereditary cancer testing, gene panels, exome testing, and single gene testing, delivered through partnership with Ambry Genetics.
• Panorama NIPT Test Non-invasive prenatal screening test (NIPT) using advanced bioinformatics to evaluate fetal DNA in maternal blood for chromosomal abnormalities, available from 9 weeks gestation, delivered through partnership with Natera.
• Harmony Non-Invasive Prenatal Test (NIPT) Non-invasive prenatal test (NIPT) for fetal chromosomal abnormalities, studied in more than 48 peer-reviewed publications, available from 10 weeks gestation for singleton, twin, and IVF pregnancies, delivered through partnership with Ariosa Diagnostics.
• High Sensitive Troponin T Cardiac biomarker test for diagnosing heart attacks and detecting heart damage through measurement of troponin proteins in the blood.
• Lipoprotein (a) Test Blood test measuring Lipoprotein(a) levels, an independent risk factor for cardiovascular disease, heart attacks, and stroke.
• Thyroid Stimulating Hormone Receptor Antibody (TRAb) Test for differential diagnosis of hyperthyroidism and Graves' disease, risk assessment for neonatal thyrotoxicosis, and evaluation of Graves' disease relapse.
• Thyroid-Stimulating Immunoglobulin (TSI) Test used to monitor Graves' disease therapy response, predict remission or relapse, confirm Graves' ophthalmopathy, and predict neonatal thyroid hyperthyroidism.
• Preeclampsia Screening (SFLT-1/PLGF Ratio) Screening test utilising the ratio between PLGF (placental growth factor) and SFLT-1 as a risk indicator for preeclampsia, detectable up to 5 weeks prior to onset.
• QuantiFERON-TB Gold Plus (QFT-Plus) Blood test for detection of Mycobacterium tuberculosis with greater than 95% sensitivity, using innovative CD8+ T cell technology for more precise assessment of cell-mediated immune response to TB infection.
• Ovarian Malignancy Algorithm (ROMA) Qualitative serum test combining HE4, CA 125, and menopausal status results into a numerical score to assist in evaluating ovarian malignancy probability in pre-menopausal and post-menopausal women.

Quantifiable outcome

• Capability to process over 10,000 patient episodes per day
• +1 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Partnerships

Five partnerships are on record, tiered core and major.

• RochecoreTechnology or IntegrationRoche provides the total laboratory automation system installed at Innoquest's main laboratory. This partnership enables high-volume diagnostic testing capability of over 10,000 patient episodes per day.
• Nightingale HealthcoreTechnology or IntegrationHealthIQ product line powered by Nightingale Health's technology. Nightingale Health's technology provides scientifically scrutinized insights for chronic disease risk assessment with over 600 peer-reviewed publications and regulatory approvals. Tests are conducted in Innoquest's ISO 15189- and CAP-accredited laboratory.
• Ambry GeneticsmajorTechnology or IntegrationAmbry Genetics provides genetic testing capabilities including over 1,000 genetic tests, with more than 100 genetic counselors and clinical genomic expertise. Innoquest offers Ambry Genetics tests as part of their comprehensive test menu.
• Natera (Panorama NIPT)majorTechnology or IntegrationPanorama non-invasive prenatal screening test (NIPT) from Natera for fetal chromosomal abnormalities. Uses advanced bioinformatics technology to evaluate fetal DNA in maternal blood.
• Ariosa Diagnostics (Harmony)majorTechnology or IntegrationHarmony Non-Invasive Prenatal Test (NIPT) offered through partnership. Harmony is proven in more than 48 peer-reviewed publications with superior performance against first-trimester screening for Down syndrome.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Quest Diagnostics: Large US-based clinical reference laboratory offering routine and specialty diagnostics (clinical chemistry, immunoassays, genetics, infectious disease) to physicians and hospitals globally. Directly comparable as a clinical lab services operator; serves as the global scale benchmark for an aspiring regional player like Innoquest.
• Laboratory Corporation of America (Labcorp): Global clinical laboratory network providing routine, esoteric, and genetic testing through B2B channels to hospitals, physicians, and biopharma. Closely comparable in operating model, test-menu breadth, and physician-customer orientation; differs in scale and geographic footprint.
• Sonic Healthcare: Australian-headquartered medical diagnostics company operating lab services across Australasia, Europe, and the US. Highly comparable as a multi-region clinical and specialty lab provider pursuing physician and hospital channels — the most relevant established international peer for Innoquest's SEA ambition.
• Eurofins Scientific: Global laboratory services group operating in clinical diagnostics and specialty testing. Comparable as a large, multi-region clinical lab operator leveraging automated platforms and broad test menus — relevant scale and geographic comparator for an expanding community-based lab.
• Unilabs: European-headquartered clinical diagnostics and reference laboratory group with operations across several countries. Comparable in operating model — community lab service via B2B channel with broad specialty menu — and offers a relevant template for cross-border expansion that a Singapore-based lab could follow.

Regional players

• SRL Diagnostics: Pan-Asia clinical diagnostics network headquartered in India with operations across several Asian markets. Highly comparable in business model (pathology/clinical lab services to clinicians and hospitals), test menu breadth (including NIPT and specialty panels), and stage of regional expansion — directly relevant peer in the Asian community-lab space.
• Parkway Laboratories (IHH Healthcare): Diagnostics arm of IHH Healthcare, operating laboratories within Mount Elizabeth, Gleneagles, and other Parkway hospitals in Singapore and Malaysia. Strong direct peer as the dominant hospital-embedded lab operator in Singapore, competing with Innoquest for the same hospital-channel work.
• Thomson Hospital Laboratories (TMC Life Sciences): Diagnostics and laboratory services arm of TMC Life Sciences, operating hospitals and labs in Malaysia and Singapore. Comparable as a regional, hospital-affiliated community/specialty lab — relevant given Innoquest's stated intent to expand into Malaysia and the rest of SEA.

Direct peers

• HealthLab (Singapore): Singapore-based clinical diagnostic laboratory offering routine and specialty testing with phlebotomy and home-collection services. Closest direct peer — domestic Singapore community lab serving clinicians, hospitals and patients with a similar service profile and competitive set.

Emerging players

• Quest Laboratories (Singapore) / Doctor Anywhere Labs: Emerging Singapore-based digital-health-linked diagnostics providers combining telehealth access with in-house or partnered lab testing. Comparable as it targets the same physician- and consumer-driven diagnostic demand in Singapore, illustrating both a competitor and a partnership pathway for Innoquest.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@InnoquestDiagnostics/videos
• Facebookfacebook.com/Innoquest.SG
• LinkedInlinkedin.com/company/innoquest-diagnostics
• Instagraminstagram.com/innoquestsg

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Innoquest Diagnostics